4586 — Medrx Co Income Statement
0.000.00%
- ¥3bn
- ¥2bn
- ¥258m
Annual income statement for Medrx Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 115 | 8.35 | 59.5 | 29.5 | 258 |
Cost of Revenue | |||||
Gross Profit | 111 | 6.09 | 56.9 | 27.1 | 258 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,200 | 1,054 | 1,155 | 963 | 1,099 |
Operating Profit | -1,084 | -1,045 | -1,096 | -933 | -841 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1,107 | -1,058 | -1,109 | -930 | -803 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,115 | -1,060 | -1,111 | -933 | -807 |
Net Income Before Extraordinary Items | |||||
Net Income | -1,115 | -1,060 | -1,111 | -933 | -807 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1,115 | -1,060 | -1,111 | -933 | -807 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -70.5 | -50.1 | -43.9 | -26.8 | -17.8 |
Dividends per Share |